What Burning Rock Biotech Ltd does.

We aim to transform precision oncology and early cancer detection. We are China’s leading NGS-based cancer therapy selection company. Our cancer therapy selection platform is built upon our advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model.

Our advanced technology platform integrates cutting-edge proprietary cancer therapy selection technologies using both tissue and liquid biopsies, including assay biochemistry, bioinformatics and a patented laboratory information management system. Our proprietary HS library preparation technology allows us to work with poor quality and limited volume samples and enables enhanced sensitivity—capabilities that are critical to effectively deploying NGS-based cancer therapy selection, especially in China. Our in-depth cancer genomics insights, accumulated from the large number of tests we have performed since our inception, enable us to process and accurately analyze genomic information. We have achieved a turnaround time of approximately six days for regular oncology products, approximately twenty-five days for MRD products and approximately nine days for early detection products.

Revenue and profit, by fiscal year.

More on BNR.

• Burning Rock Biotech Ltd summary
• Burning Rock Biotech Ltd financial statements
• Burning Rock Biotech Ltd key metrics
• Burning Rock Biotech Ltd health scores and style box
• Burning Rock Biotech Ltd earnings
• Burning Rock Biotech Ltd dividends
• Burning Rock Biotech Ltd valuation
• Burning Rock Biotech Ltd ownership and insiders
• Burning Rock Biotech Ltd peers

Figures from Burning Rock Biotech Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.